Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Smoking Cessation in Schizophrenia Patients with Tardive Dyskinesia
NCT03495024Phase 4Recruiting
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of varenicline in Tobacco Use Disorder (TUD), sponsored by Corporal Michael J. Crescenz VA Medical Center. Primary endpoint: Self-reported 7-day point prevalence of abstinence at 12 weeks. Started Jan 2019; status: recruiting.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03495024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495024.